Ivabradine Teva

Ivabradine, the active ingredient in Ivabradine Teva, is an If channel inhibitor presented as an oral tablet for oral use. It treats chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate, benefiting conditions where rate control improves outcomes. - Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves exercise capacity and lowers hospitalization risk through heart‑rate reduction. - Patients intolerant to beta‑blockers: provides a non‑beta‑blocker option for heart‑rate control in coronary disease.

Adverse reactions are reported across clinical use.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below the intended therapeutic range. - Headache: mild to moderate intensity. - Dizziness or vertigo: often related to reduced heart rate. - Fatigue: general feeling of tiredness. - Blurred vision: occasional visual acuity changes.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Visual loss or persistent retinal disturbances. - Acute coronary syndrome in vulnerable patients. - Allergic reactions such as rash or angioedema.

Before initiating therapy, clinicians should evaluate cardiovascular status and potential contraindications. - Heart‑rate monitoring: ensure baseline rate is appropriate before dosing. - Hepatic impairment: use caution in moderate to severe liver disease. - Concomitant bradycardic agents: avoid combining with beta‑blockers or digoxin without supervision. - Sick‑sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store below 25°C: keep in the original pack, protect from moisture.

Ivabradine may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma levels. - Other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Drugs that prolong QT interval: additive risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - Antihypertensive agents: monitor blood pressure for additive effects. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Herbal supplements affecting CYP enzymes: assess patient use.